Revenue for Q1 2025 was $15.5 billion, a decrease of 2% year-over-year, or a 1% increase when excluding foreign exchange impacts. Gross margin improved to 82.2%, driven by favorable product mix.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Merck’s ability to consistently expand gross margin (+310 bps YoY to 76.3% in Q4 2024) highlights the impact of operational efficiency and a favorable product mix in driving more profitable ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

We expect the company to maintain its higher gross margins on the back of better product mix. Merck may also secure the regulatory approval for clesrovimab – an antibody for RSV treatment in ...

Current Position of Merck & Co Currently trading with a volume of 12,034,764, the MRK's price is up by 1.57%, now at $74.62. RSI readings suggest the stock is currently is currently neutral ...

We expect the company to maintain its higher gross margins on the back of better product mix. Merck may also secure the regulatory approval for clesrovimab – an antibody for RSV treatment in ...

Merck’s adjusted gross margin improved by 40 basis points to 78%, thanks to a favorable product mix. The company’s adjusted earnings per share reached $2.22.

The increase was primarily due to the favorable impact of product mix ... MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 : 2024 2023 2Q ...

Earnings Call Insights: Merck & Co., Inc. (MRK) Q1 2025. Management View. CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product ...